
Oryn Therapeutics advances immune-reprogramming peptide platform with new leadership and board members
Oryn Therapeutics is progressing its next-generation Orynotide™ macrocyclic peptide platform aimed at treating inflammatory and autoimmune diseases through immune reprogramming rather than suppression. The company appointed Guy Rosenthal as CEO and e...

